Nautilus Biotechnology (NAUT) Change in Account Payables (2020 - 2026)
Nautilus Biotechnology (NAUT) posted Change in Account Payables of -$304000.0 for Q2 2026, down 252.0% sequentially from $200000.0 in Q1 2026, and down 480.0% YoY from $80000.0 in Q2 2025.
Nautilus Biotechnology (NAUT) Change in Account Payables (2020 - 2026) Analysis & Trends
Nautilus Biotechnology has reported Change in Account Payables for 7 years, with the latest figure at -$304000.0 in Q2 2026.
- Quarterly Change in Account Payables fell 480.0% year-over-year to -$304000.0 in Q2 2026, while the trailing twelve-month figure through Jun 2026 was -$122000.0 (up 61.99% YoY) and the FY2025 annual result came in at -$69000.0, up 88.06% from the prior year.
- Change in Account Payables eased to -$304000.0 in Q2 2026 per NAUT's latest filing, from $200000.0 in the prior quarter.
- Over five years, Change in Account Payables peaked at $371000.0 in Q4 2023 and troughed at -$543000.0 in Q4 2024.
- A 5-year average of -$51055.6 and a median of -$9000.0 in 2025 frame the typical range for Change in Account Payables.
- The sharpest annual moves came in 2022 and 2026: Change in Account Payables plunged 25000.0% in 2022, then jumped 252.67% in 2026.
- Over 5 years, Change in Account Payables stood at $289000.0 in 2022, then gained by 28.37% to $371000.0 in 2023, then slumped by 246.36% to -$543000.0 in 2024, then soared by 100.37% to $2000.0 in 2025, then slumped by 15300.0% to -$304000.0 in 2026.
- According to Business Quant data, Change in Account Payables over the past three periods registered -$304000.0, $200000.0, and $2000.0 for Q2 2026, Q1 2026, and Q4 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Account Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | -66.70 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -8.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 37.53 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Nautilus Biotechnology | 120.16 Mn | 120.16 Mn | 175,000.00 | -304,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -304,000.00 |
| Jun 30, 2026 | -304,000.00 |
| Mar 31, 2026 | 200,000.00 |
| Mar 31, 2026 | 200,000.00 |
| Dec 31, 2025 | 2,000.00 |
| Dec 31, 2025 | 2,000.00 |
| Sep 30, 2025 | -20,000.00 |
| Sep 30, 2025 | -20,000.00 |
| Jun 30, 2025 | 80,000.00 |
| Jun 30, 2025 | 80,000.00 |
| Mar 31, 2025 | -131,000.00 |
| Mar 31, 2025 | -131,000.00 |
| Dec 31, 2024 | -543,000.00 |
| Dec 31, 2024 | -543,000.00 |
| Sep 30, 2024 | 273,000.00 |
| Sep 30, 2024 | 273,000.00 |
| Jun 30, 2024 | -402,000.00 |
| Jun 30, 2024 | -402,000.00 |
| Mar 31, 2024 | 94,000.00 |
| Mar 31, 2024 | 94,000.00 |